Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
What recent performance says about Aktis Oncology
Aktis Oncology (AKTS) has drawn fresh attention after recent trading, with the stock up 6.4% on the day and 9.3% over the past week, even as it is down 4.3% over the past month.
See our latest analysis for Aktis Oncology.
For context, Aktis Oncology's recent 1 day share price return of 6.38% and 7 day share price return of 9.30% come after a 30 day share price return that is down 4.33% and a year to date share price return that is down 9.20%. This suggests that short term momentum is improving after a softer stretch.
If Aktis Oncology's move has you looking beyond a single stock, this may be a good moment to broaden your search with 34 healthcare AI stocks
With Aktis Oncology's shares recently higher but still below the average analyst price target of US$32.25, the key question is whether the stock is still undervalued or if the market is already pricing in future growth.
Preferred Price-to-Book of 2.2x: Is it justified?
Aktis Oncology currently trades on a P/B of 2.2x, which places the stock below both the wider US Biotechs industry and its closest peer group on this metric.
The P/B ratio compares the company's market value with the book value of its net assets. It is often used for early stage or loss making biotechs where earnings are not yet a guide. For Aktis Oncology, this means investors are paying 2.2 times the accounting value of its equity despite the company being unprofitable and reporting a net loss of $67.07 million on revenue of $8.28 million.
Compared with the US Biotechs industry average P/B of 2.5x and a peer average of 3.5x, the current 2.2x multiple suggests the stock is priced more cautiously. The market is assigning a lower valuation to each dollar of equity than it does to both the sector and similar companies, even though analysts expect revenue to grow 51.7% per year, while forecasts also indicate that earnings are set to decline and the company is not expected to reach profitability over the next 3 years.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 2.2x
However, you still need to weigh the company's ongoing losses and dependence on early stage clinical results, either of which could quickly change how investors view the stock.
Find out about the key risks to this Aktis Oncology narrative.
Next Steps
The mix of recent share price moves, cautious valuation and early stage risk might feel finely balanced. It makes sense to review the numbers and sentiment for yourself, weigh what matters most to your approach, and then check the 2 key rewards and 2 important warning signs
Looking for more investment ideas?
If Aktis Oncology has your attention, do not stop here. Use this momentum to scout other opportunities that could fit your portfolio just as well.
-
Spot potential value upside by scanning 48 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their underlying strength.
-
Strengthen your income stream by reviewing 10 dividend fortresses that focus on higher yielding companies built around consistent cash returns to shareholders.
-
Prioritise resilience by tracking 69 resilient stocks with low risk scores designed to highlight companies with more measured risk profiles and steadier underlying business characteristics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AKTS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
